Back to Search Start Over

Vaccination with RSV M209-223 peptide promotes a protective immune response associated with reduced pulmonary inflammation.

Authors :
Fazolo, Tiago
Gassen, Rodrigo Benedetti
de Freitas, Deise Nascimento
Borges, Thiago J.
Rigo, Maurício Menegatti
da Silva, Rodrigo Dornelles
Maito, Fábio
Cunha, Aline
Gasparin Bueno Mendes, Daniel Augusto
Báfica, André
Vargas, José Eduardo
de Souza, Ana Paula Duarte
Bonorino, Cristina
Source :
Antiviral Research. Sep2018, Vol. 157, p102-110. 9p.
Publication Year :
2018

Abstract

Respiratory syncytial virus (RSV) is the most common etiologic agent in severe infections of the lower respiratory tract in children with a high mortality rate. However, there are still no licensed vaccines for RSV. In this study, we investigated a putative vaccine based on M 209-223 peptide. Mice vaccinated with M 209-223 peptide expanded M 209-223 -specific effector CD4 + T cells upon infection. Vaccination resulted in increased numbers of regulatory T cells (Treg) and Th1 cells, and decreased numbers of Th2 cells. In addition, vaccination with M 209-223 peptide, protected mice from infection and prevented lung inflammation, leading to increase in IL-10 and IFN-γ production by lung CD4 + T cells. Treg depletion with anti-CTLA4 antibodies abrogated protection induced by peptide vaccination. Our results support vaccination with M 209-223 peptide as an important strategy to generate protection, both systemic and local, by memory RSV-specific CD4 + T cells in mice. Contrarily to inactivated RSV particles, M 209-223 peptide vaccination is capable of not only promoting viral clearance, but also reducing inflammatory processes in lungs upon infection. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
01663542
Volume :
157
Database :
Academic Search Index
Journal :
Antiviral Research
Publication Type :
Academic Journal
Accession number :
131145840
Full Text :
https://doi.org/10.1016/j.antiviral.2018.07.007